Antibody quality has long loomed as a significant concern for proteomics research, with much discussion in the field of what validation steps are needed and what data vendors should provide to ensure the performance of a given affinity agent.

According to Nader Rifai, director of clinical chemistry at Children's Hospital Boston and the editor-in-chief of the journal Clinical Chemistry, these concerns have recently taken on a new urgency due to the appearance on the market of a large number of faulty antibodies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.